PYPD NASDAQ
PolyPid Ltd.
1W: +14.9%
1M: +6.8%
3M: +13.6%
YTD: +11.5%
1Y: +72.6%
3Y: -60.8%
5Y: -98.3%
$4.85
+0.09 (+1.89%)
Weekly Expected Move ±6.4%
$4
$4
$5
$5
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$49.4M
52W Range2.44-5.12
Volume212,075
Avg Volume58,795
Beta1.41
Dividend—
Analyst Ratings
Company Info
CEODikla Czaczkes Akselbrad
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-26
Websitepolypid.com
18 Hasivim Street
Petah Tikva 4959376
IL
Petah Tikva 4959376
IL
972 7 4719 5700
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest News
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PolyPid Ltd. Q1 2026 Earnings Call Summary
PolyPid (PYPD) Q1 2026 Earnings Transcript
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jacobovitz Yitzchak | 0 | — | 2026-03-18 | |
| Warshavsky Ori | 0 | — | 2026-03-18 | |
| Barenholz Yechezkel | 0 | — | 2026-03-18 | |
| Krinsky Itzhak | 0 | — | 2026-03-18 | |
| Akselbrad Dikla Czac | 0 | — | 2026-03-18 |